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Abstract In this study, we examined the contribution made by
CD45 to B cell antigen receptor (BCR)-induced activation of
mitogen-activated protein kinase (MAPK) family members. We
found that CD45 negatively regulated BCR-induced c-Jun NH2-
terminal kinase (JNK) and p38 activation in immature WEHI-
231 cells, whereas in mature BAL-17 cells, CD45 positively
regulated JNK and p38 activation and negatively regulated
extracellular signal-regulated kinase activity. Furthermore,
cooperative action of JNK and p38 dictated BCR-induced
inhibition of growth. Thus, CD45 appears to differentially
regulate BCR-induced activation of MAPK members, and can
exert opposing effects on JNK and p38 in different cellular
milieu, controlling the B cell fate. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Engagement of B cell antigen receptor (BCR) by anti-IgM
antibody (Ab) or multivalent antigens rapidly induces tyrosine
phosphorylation of a number of cellular proteins [1]. Signals
are then propagated downstream, ultimately leading to con-
trol gene expression and to B cell activation, death or anergy,
depending upon the cell’s developmental stage, the antigen
structure, and the presence or absence of co-stimulatory sig-
nals [2,3]. Regardless of the context within which stimulation
occurs, BCR signaling is dependent upon the proximal acti-
vation of protein tyrosine kinases (PTKs), in particular Src-
family PTKs (Lyn, Blk, Lck, Fyn and Fgr), Syk and Btk.
Accumulating evidence suggests that one of the crucial regu-
lators of BCR signaling is the receptor-type protein tyrosine
phosphatase (PTP), CD45 [4^6]. CD45 has been implicated in
both T and B cell activation based on experiments using
CD45-de¢cient cells [7^10] and cells from CD45 gene-targeted
mice [11,12]. Although it is now clear that Src-family PTKs
serve as targets for CD45, the precise mode of CD45 action
remains controversial [13^15]. Furthermore, it is still unclear
as to how CD45-mediated activation or inactivation of Src-
family PTKs is transduced into downstream signaling path-
ways.
Mitogen-activated protein kinases (MAPKs) are a group of
serine/threonine-speci¢c protein kinases activated by a wide
variety of extracellular signals [16,17]. In mammalian cells,
three related but distinct members of the MAPK family
have been identi¢ed: extracellular signal-regulated kinase
(ERK), c-Jun NH2-terminal kinase/stress-activated protein ki-
nase (JNK/SAPK), and p38 MAPK (p38). Integration of sig-
nals from any single member of this family may dictate cel-
lular proliferation, di¡erentiation or apoptosis among other
cellular processes [16,17].
Our previous studies demonstrated that CD45 exerts oppos-
ing e¡ects on BCR-induced signaling depending on the state
of B cell maturation [9,10]. In CD45-negative clones from
immature WEHI-231 cells, Ca2 mobilization was delayed
but enhanced, and growth inhibition and apoptosis were
more striking [9]. In mature BAL-17 cells, by contrast,
BCR-induced Ca2 mobilization and growth inhibition are
positively regulated by CD45 [10]. To elucidate the molecular
basis of the di¡erential regulation of growth by CD45, in this
study, we focussed on the MAPK pathways. We found that
the e¡ects of CD45 on BCR-induced activation of JNK and
p38 were opposing in WEHI-231 and BAL-17 and correlated
with growth regulation in respective cells. We further ob-
served that the cooperative action of JNK and p38 dictates
the fate of B cells triggered by BCR ligation via a process that
is dependent upon CD45.
2. Materials and methods
2.1. Cells
The murine, immature B cell line WEHI-231, its CD45-de¢cient
clone, 10-5, the mature B cell line BAL-17, and its CD45-de¢cient
clone, 44, were all described in previous reports [9,10]. These cells
were maintained in RPMI 1640 supplemented with 10% fetal bovine
serum, 50 mM 2-ME, 100 mg/ml streptomycin and 100 U/ml penicillin
(complete medium).
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2.2. Antibodies and reagents
Goat F(abP)2 fragments of anti-mouse IgM Ab were purchased
from ICN Pharmaceuticals, Inc. (Aurora, OH, USA). PD98059 and
SB203580 were obtained from New England BioLabs, Inc. (Beverly,
MA, USA) and Calbiochem-Novabiochem Corp. (La Jolla, CA,
USA), respectively. Rabbit anti-mouse phospho-speci¢c JNK Ab
was purchased from New England BioLabs. Rabbit anti-mouse
ERK-2 Ab, anti-JNK Ab, anti-p38 Ab, and puri¢ed ATF-2 protein
were all from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
2.3. Cell stimulation and Western blot analysis
Cells were initially incubated for 3 h at 37‡C and then stimulated
with 20 mg/ml F(abP)2 fragments of anti-IgM Ab for 5^30 min, after
which the reactions were terminated with ice-cold PBS containing
2 mM Na3VO4 and 2 mM EDTA (PBS-VE). The cells were solubi-
lized in TNE lysis bu¡er (1% Nonidet P-40, 10 mM Tris^HCl, pH 7.5,
150 mM NaCl, 2 mM Na3VO4, 2 mM EDTA, 1 mM NaF, 10 mM
sodium pyrophosphate) supplemented with protease inhibitors. The
lysates were centrifuged at 10 000Ug at 4‡C for 30 min, and the
supernatants were separated on 10% SDS^PAGE gels and transferred
to nitrocellulose membrane. Western blots were incubated with Abs
against ERK, JNK and p38 and then with mouse anti-rabbit IgG-
alkaline phosphatase (Jackson Immunoresearch Laboratories, Inc.,
West Grove, PA, USA) or horseradish peroxidase-conjugated anti-
rabbit IgG (Santa Cruz Biotechnology). The blots were visualized
using an Alkaline Phosphatase Conjugate Substrate kit (Bio-Rad Lab-
oratories, Hercules, CA, USA), or ECL Western blotting detection
reagent (Amersham Pharmacia Biotech, Ltd., Buckinghamshire, UK).
2.4. In vitro kinase assays for MAPKs and MAPKAPK-2
Cell lysates were immunoprecipitated with protein G-Sepharose
beads bound with Abs against ERK2, JNK, p38 and MAPKAPK-2.
After washing with TNE lysis bu¡er and kinase bu¡er for MAPKs
(50 mM Tris^HCl, pH 7.5, 10 mM MgCl2, 1 mM DTT, 100 mM
Na3VO4, 100 mM ATP) or kinase bu¡er for MAPKAPK-2 (20 mM
MOPS, pH 7.2, 25 mM L-glycerophosphate, 5 mM EGTA, 75 mM
MgCl2, 1 mM DTT, and 1 mM Na3VO4), the immunoprecipitates
were incubated for 20^30 min at 30‡C in kinase bu¡er containing
5^10 mCi of [Q-32P]ATP, 500 mM ATP and the appropriate sub-
strates: myelin basic protein (MBP) for ERK, glutathione S-transfer-
ase (GST)-c-Jun1-79 fusion protein (a gift from Dr. G. Koretzky) for
JNK, puri¢ed ATF-2 protein for p38, and murine heat shock protein
(hsp) 25 (Sigma Chemical Co., St. Louis, MO, USA). The reactions
were terminated by adding Laemmli sample bu¡er, after which the
samples were subjected to SDS^PAGE. The phosphorylated sub-
strates were visualized by autoradiography. The intensities of bands
were measured with a Bio-Rad imaging densitometer, and the results
were expressed as percent control activity.
2.5. Transfection
Cells were suspended in 1 ml of complete cytomix bu¡er (120 mM
KCl, 0.15 mM CaCl2, 10 mM K2HPO4/KH2PO4, pH 7.6, 25 mM
HEPES, pH 7.6, 2 mM EGTA, pH 7.6, 5 mM MgCl2, 2 mM ATP,
and 5 mM glutathione). Aliquots of cell suspension (400 Wl ; 2U107
cells) were added to a cuvette together with 30 Wg of either pEFII
expression vector containing a gene encoding a HA-tagged dominant-
negative SEK1 mutant (SEK-AL) [18], which had been excised from
pcDNA3 Zeo, or the empty vector (a gift from Dr. G. Koretzky). The
cells were transfected by electroporation at 270 V, 950 WF for 20 ms,
after which they were gently mixed, cultured in complete culture me-
dium for 24 h, and subjected to functional analysis.
2.6. Assay for DNA synthesis
Cells (5U103) were incubated in triplicate for 24 h in 0.2 ml of
complete medium with or without F(abP)2 fragments of goat anti-
mouse IgM Ab. To assess DNA synthesis, 0.5 WCi of [3H]thymidine
was added to each well for the ¢nal 4 h. The cells were then harvested
on glass¢ber ¢lters using a semi-automatic Skatron harvester, and
thymidine incorporation was measured in a Beckman liquid scintilla-
tion counter. The results were expressed as percent control DNA syn-
thesis.
3. Results
3.1. Regulation of BCR-induced MAPK activation by CD45 in
WEHI-231 cells
To de¢ne the molecular basis of the di¡erential regulation
by CD45, we ¢rst examined the e¡ect of CD45 de¢ciency on
the activation of ERK, JNK and p38 in WEHI-231 cells.
WEHI-231 cells and its CD45-de¢cient, clone 10-5 were
stimulated with 20 Wg/ml F(abP)2 fragments of anti-IgM Ab
for 5^30 min, and then in vitro kinase assays were performed
with appropriate substrates. Results of a representative experi-
ment are shown in Fig. 1. BCR-induced ERK activation in
the parent peaked within 5 min and was still detected after
30 min, whereas ERK activity returned to baseline by 30 min
in clone 10-5 cells. However, this di¡erence in kinetics was
not statistically signi¢cant in four independent experiments
(Fig. 3). By contrast, BCR-induced activation of JNK and
p38 was signi¢cantly more pronounced in clone 10-5 than in
the parent (Figs. 1 and 3). These results suggest that in
WEHI-231 cells, CD45 may negatively a¡ect activation of
both JNK and p38.
3.2. Regulation of BCR-induced MAPK activation by CD45 in
BAL-17 cells
BCR-induced MAPK activation was then examined in
BAL-17 and the CD45-negative, clone 44. As shown in Fig.
2, a representative experiment demonstrates that BCR stimu-
lation elicited larger increases in ERK activity in clone 44 cells
than in the parent. Conversely, although JNK activity was
strongly induced by BCR ligation in the parent, it was com-
pletely ablated in clone 44. Similarly, activation of p38 was
signi¢cantly reduced in clone 44 as compared with the parent.
As shown in Fig. 3, all the di¡erences were statistically sig-
ni¢cant. Thus, in BAL-17 cells, CD45 seems to negatively
Fig. 1. BCR-induced activation of MAPKs in WEHI-231 cells and
its CD45-de¢cient clone. WEHI-231 and clone 10-5 cells were cul-
tured with 20 Wg/ml F(abP)2 fragments of anti-IgM Ab for 5^30
min, and in vitro immune complex kinase assays were performed
for ERK, JNK and p38 using MBP, GST-c-Jun and GST-ATF-2,
respectively, as substrates. Total cell lysates were immunoblotted
with Abs against ERK, JNK and p38. The results are representative
of four independent experiments.
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regulate BCR-induced activation of ERK but positively regu-
late activation of JNK and p38.
Taken two sets of experiments together, the results suggest
that the regulatory e¡ect of CD45 on BCR-induced activation
of ERK di¡er from its e¡ects on activation of JNK and p38,
and more importantly, the regulatory e¡ects of CD45 seem to
be opposing in WEHI-231 and BAL-17 cells (Fig. 3). Given
that growth inhibition is negatively regulated by CD45 in
WEHI-231 cells [9] and positively regulated in BAL-17 cells
[10], it is of particular note that the regulatory e¡ect of CD45
on the ¢nal outcome for the cells correlates well with its e¡ect
on activation of JNK and p38.
3.3. ERK or p38 alone does not contribute to BCR-induced
growth inhibition
To more directly explore the respective contributions of
each MAPK family member to BCR-induced growth inhibi-
tion, we ¢rst examined the e¡ect of PD98059, a speci¢c in-
hibitor of MEK. BAL-17 cells were preincubated for 1 h with
graded concentrations of PD98059, after which they were cul-
tured with anti-IgM Ab in the presence of PD98059 for 24 h.
As shown in Fig. 4A, in vitro kinase assays revealed that
PD98059 inhibited BCR-induced activation of ERK by 74%
at 100 WM, the highest dose that could be tested. However,
PD98059 at 100 WM had no e¡ect on growth inhibition (Fig.
4A), indicating that ERK activation contributed little if at all
to BCR-induced inhibition of BAL-17 cell growth.
We then examined the role of p38 in growth inhibition
using SB203580, a speci¢c inhibitor for p38. BAL-17 cells
were cultured with SB203580 as above. Preincubation for 1 h
with 40 mM SB203580, the highest non-toxic dose, reduced
subsequent BCR-induced p38 activation by 71% as measured
by the activity of MAPKAP kinase-2 (MAPKAPK-2) and
had a minimal inhibitory e¡ect on growth inhibition. Thus,
p38 activation alone may not contribute signi¢cantly to
growth inhibition in BAL-17.
3.4. JNK acts cooperatively with p38 to dictate BCR-induced
growth inhibition
To evaluate the importance of JNK, BAL-17 cells were
transfected with a plasmid containing a dominant-negative
form (DN) of SEK1 (DN-SEK1) [18], an upstream activator
of JNK (Fig. 5A). 24 h later, the transfected cells were cul-
tured with or without SB203580 or PD98059 and then stimu-
lated with anti-IgM Ab for 24 h, after which DNA synthesis
and the activation of ERK, JNK and p38 was assayed. Tim-
ing of the treatment with SB203580 and PD98059 was the
same as described above. The transfection of DN-SEK1 re-
duced JNK activity by 54% with little or no e¡ect on ERK
and p38 activities. Under this condition, growth inhibition
was reduced by about 20% (Fig. 5B). Strikingly, when the
DN-SEK1 transfectants were treated with 10 WM SB203580,
Fig. 2. BCR-induced activation of MAPKs in BAL-17 cells and its
CD45-de¢cient clone. BAL-17 and clone 44 cells were cultured with
20 Wg/ml F(abP)2 fragments of anti-IgM Ab for 5^30 min, and in vi-
tro immune complex kinase assays were performed for ERK, JNK
and p38 using MBP, ATF-2 and GST-ATF-2, respectively, as sub-
strates. The total cell lysates were immunoblotted with Abs against
ERK, JNK and p38. The results are representative of four inde-
pendent experiments.
Fig. 3. CD45 exerts opposing e¡ects on MAPK family members de-
pending on the maturational stage of B cells. Data obtained from
four independent in vitro kinase assays were subjected to densito-
metric analysis, and the intensity of each band was normalized to
the amount of kinase assayed. The mean relative intensities þ S.E.M.
of the parental cells (a) and CD45-de¢cient clones (F) were plotted
as a function of time; the intensity of an unstimulated group arbi-
trarily set to 1. *Represents P6 0.05 by Student’s t-test.
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but not 50 WM PD98059, the BCR-induced growth inhibition
was signi¢cantly rescued (Fig. 5B). Given that either DN-
SEK1 transfection or SB203580 alone did not have signi¢cant
e¡ects on this process, the results may mean that BCR-in-
duced growth inhibition is dictated by actions of JNK and
p38.
4. Discussion
Three major ¢ndings are presented herein: ¢rst, the regu-
latory e¡ects of CD45 on BCR-induced activation of ERK
may di¡er from the e¡ects on JNK and p38 in both WEHI-
231 and BAL-17 cells ; second, the e¡ects of CD45 on JNK
and p38 seem to be opposing in WEHI-231 and BAL-17 cells ;
and third, activation of both JNK and p38 is required for
BCR-initiated inhibition of growth in BAL-17 cells.
We have previously reported that in WEHI-231 cells, CD45
negatively regulates Lyn kinase activity [19,20], and BCR-in-
duced growth inhibition and apoptosis [9]. The present study
further demonstrates that negative regulation of Lyn by CD45
correlates with the regulatory mode of downstream events
such as activation of JNK and p38 and induction of growth
Fig. 4. Reduction in ERK and p38 activities does not a¡ect BCR-induced growth inhibition. BAL-17 cells were pretreated for 1 h with graded
concentrations of the MEK1-speci¢c inhibitor, PD98059 (A) and the p38-speci¢c inhibitor, SB203580 (B), after which they were cultured with
20 Wg/ml F(abP)2 fragments of anti-IgM Ab for 24 h. DNA synthesis was measured as described in Section 2. The results were expressed as
mean percent growth inhibition { = 100 [13(anti-IgM Ab added)/(no Ab added)]} þ S.E.M. of three independent experiments. Control cpms
(without anti-IgM Ab) were not signi¢cantly di¡erent among groups. The e¡ects of PD98059 and SB203580 on the activation of ERK-2 and
p38 were determined by in vitro kinase assays of ERK and MAPKAPK-2 using MBP and hsp 25, respectively, as substrates. The results were
expressed as mean control kinase activity of three experiments with the activity of untreated cells being 100%.
C
Fig. 5. JNK and p38 synergistically rescue BCR-induced inhibition
of BAL-17 cell growth. A: Expression of HA-tagged DN-SEK1.
BAL-17 cells were transfected with HA-tagged DN-SEK1 or an
empty vector, and the expression of DN-SEK1 was assessed by im-
munoblotting with anti-HA mAb. B: Transfection of DN-SEK1
and exposure to SB203580, but not to PD98059, signi¢cantly re-
duced BCR-induced inhibition of BAL-17 cell growth. Cells trans-
fected with DN-SEK1 or empty vector were cultured with 20 Wg/ml
F(abP)2 fragments of anti-IgM Ab in the presence or absence of
50 mM PD98059 or 10 WM SB203580 for 24 h, and DNA synthesis
was assayed as described as above. The results were expressed as
mean percent growth inhibition þ S.E.M. of four independent experi-
ments. *Represents a statistically signi¢cant di¡erence (P6 0.05 by
Student’s t-test) between vector and DN-SEK transfectants. Activa-
tion of ERK and p38 was measured by kinase assays using MBP
and hsp 25, respectively, as substrates. Activation of JNK was ex-
amined by immunoblotting with anti-pJNK Ab. Mean percent con-
trol values of four experiments were calculated by densitometric
analysis. S.E.M. of mean percent control kinase activities were all
6 2.
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inhibition. Consistent with these ¢ndings, one recent study
conducted in the chicken DT40 B cell line suggested that
BCR-evoked MAPK activation is regulated at the level of
PTKs [21]. What is more, CD45 regulation of JNK and p38
activation parallels the induction of growth inhibition in
BAL-17 cells [10]. Our preliminary results demonstrated that
Fyn, but not Lyn, is a substrate for CD45 in BAL-17 cells.
Thus, one possibility is that opposing e¡ects of CD45 in
WEHI-231 and BAL-17 cells may be dependent on which
Src-family kinase is initially regulated by CD45. Alternatively,
there may be molecules among substrates for Lyn and Fyn or
other CD45 substrates that act as switches for positive or
negative signaling.
Data from transgenic mouse models indicate that one of the
mechanisms regulating positive and negative immune re-
sponses involves di¡erences in the nuclear signals activated
[22]. In naive B cells, a foreign Ag induces activation of
ERK, JNK, NF-UB and nuclear factor of activated T cells
(NFAT), whereas self Ag activates NFAT and ERK but not
NF-UB or JNK. Additionally, CD45-de¢cient, tolerant B cells
do not induce any of these signals [22]. Several studies have
addressed the question of which members of MAPK family
are critical to BCR-induced apoptosis or activation [21,23^
28]. For example, it has been shown that activation of ERK
appears to correlate with BCR-induced apoptosis in WEHI-
231 cells [23,24], while activation of all three members, ERK,
JNK and p38, correlates with cell survival [23]. In contrast,
other studies demonstrated that activation of JNK and p38
correlates with anti-IgM-induced apoptosis in human B104 B
lymphoma cells, which express both IgM and IgD on their cell
surfaces [25,26]. In chicken DT40 B cells, BCR-induced apo-
ptosis was blocked in Syk- and Btk-de¢cient cells, where JNK
was not activated [21,27,28], but not in wild-type or Lyn-de-
¢cient cells, where JNK was activated [21,27]. However, all
these data only suggest correlation between MAPK activation
and the ¢nal outcomes.
To examine the contribution of JNK to BCR-induced sig-
naling, we used DN-SEK1. One of the reasons is that kinase-
dead, DN-JNK is not as potent an inhibitor as DN-SEK1.
Moreover, DN-SEK1 is just as selective as DN-JNK since it
does not interfere with p38 MAPKs nor does it tie up regu-
lation of nuclear targets. Use of dominant negatives does have
limitations but at present there are no good alternatives for
the JNK pathway. Our result demonstrated that exposure of
DN-SEK1 transfectants of BAL-17 to a speci¢c p38, but not
MEK1, inhibitor synergistically rescued BCR-induced growth
inhibition, indicating for the ¢rst time a causal relationship
between activation of both JNK and p38 and induction of
growth inhibition. Because CD45 crucially regulates BCR-in-
duced growth inhibition in BAL-17 cells [10], the e¡ect of
CD45 on the ¢nal outcome of BCR signaling is likely medi-
ated in part through JNK and p38 pathways. What molecules
are then linking CD45 to the activation of MAPKs? The fact
that two small G proteins, Ras and Rac/Cdc42, respectively
regulate ERK and JNK/p38 pathways makes it reasonable to
hypothesize that CD45 may exert its di¡erential e¡ects via
Ras and Rac/Cdc42. It is also possible that CD45 a¡ects
targets situated downstream of the pathways, for example,
MAPKKKs or MAPKKs. How substrate PTKs regulated
by CD45 in turn contribute to MAPK activation in a mem-
ber-speci¢c manner is a question for future study.
In conclusion, our results suggest that signals generated
through CD45 may di¡erentially regulate BCR-induced acti-
vation of MAPK family members, eliciting opposing e¡ects in
immature and mature B cell lines. Furthermore, our data in-
dicate that JNK and p38 cooperatively dictate the BCR-in-
duced fate of B cells, a process to which CD45 contributes
positively.
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